1. Prostacyclin Pathway Agents in Action

2. Program Themes

3. 28-Year-Old Woman, 10-Year History of SLE

4. RHC and Associated Diagnostics

5. Diagnosis and Initial Therapy

6. Follow-Up 2012

7. Initial Use of Ambrisentan + Tadalafil in PAH The AMBITION Trial

8. AMBITION Results

9. Follow-Up 2013

10. Follow-Up 2016

11. Options in the Context of Dual Background Therapy

12. Sequential Combination Therapy Recommendations for WHO FC III PAH

13. Medications Targeting the PGI2 Pathway

14. Clinical Efficacy/Safety GRIPHON Trial

15. GRIPHON Treatment Effect by Subgroup

16. Follow-Up 2017

17. GRIPHON Titration and Dosing

18. Case Summary

19. Determinants of Prognosis in PAH

20. Abbreviations

21. Abbreviations (cont)